JDERX
Price
$12.35
Change
+$0.15 (+1.23%)
Updated
Dec 20 closing price
PAMCX
Price
$95.07
Change
+$1.09 (+1.16%)
Updated
Dec 20 closing price
Ad is loading...

JDERX vs PAMCX

Header iconJDERX vs PAMCX Comparison
Open Charts JDERX vs PAMCXBanner chart's image
PGIM Jennison Mid-Cap Growth R
Price$12.35
Change+$0.15 (+1.23%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth Adv
Price$95.07
Change+$1.09 (+1.16%)
VolumeN/A
CapitalizationN/A
JDERX vs PAMCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JDERX vs. PAMCX commentary
Dec 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JDERX is a Buy and PAMCX is a Hold.

FUNDAMENTALS
Fundamentals
PAMCX has more cash in the bank: 30.3B vs. JDERX (2.53B). JDERX (0.00) and PAMCX (0.00) have matching dividends . JDERX was incepted earlier than PAMCX: JDERX (20 years) vs PAMCX (25 years). JDERX is a more actively managed with annual turnover of: 38.00 vs. PAMCX (21.70). JDERX has a lower initial minimum investment than PAMCX: JDERX (0) vs PAMCX (2500). JDERX annual gain was more profitable for investors over the last year : 3.65 vs. PAMCX (1.02). PAMCX return over 5 years is better than : 3.26 vs. JDERX (-39.87).
JDERXPAMCXJDERX / PAMCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence20 years25 years-
Gain YTD3.2150.0635,091%
Front LoadN/AN/A-
Min. Initial Investment02500-
Min. Initial Investment IRAN/AN/A-
Net Assets2.53B30.3B8%
Annual Yield % from dividends0.000.00-
Returns for 1 year3.651.02358%
Returns for 3 years-39.99-13.30301%
Returns for 5 years-39.873.26-1,224%
Returns for 10 years-67.5628.18-240%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AGYS138.673.81
+2.83%
Agilysys
ACNT11.300.30
+2.73%
Ascent Industries Co
WPP52.29-0.29
-0.55%
WPP PLC
EHAB7.65-0.05
-0.65%
Enhabit
ATXI1.77-0.03
-1.67%
Avenue Therapeutics